Ackrell Capital report shows modest capital raised by U.S. publicly traded cannabis companies in 2017
Ackrell Capital report shows modest capital raised by U.S. publicly traded cannabis companies in 2017 The passage provides only aggregate financial data on small, largely unprofitable cannabis firms with no mention of high‑profile individuals, government agencies, or illicit activity. It lacks specific transactions, dates, or actors that could be pursued for investigative leads. Key insights: Only $268 million total equity and debt raised by listed cannabis firms in the 12‑month period ending Sep 30 2017.; Most companies had little to no revenue and were not profitable.; A single large $317 million financing by GW Pharmaceuticals occurred outside the reporting window.
Summary
Ackrell Capital report shows modest capital raised by U.S. publicly traded cannabis companies in 2017 The passage provides only aggregate financial data on small, largely unprofitable cannabis firms with no mention of high‑profile individuals, government agencies, or illicit activity. It lacks specific transactions, dates, or actors that could be pursued for investigative leads. Key insights: Only $268 million total equity and debt raised by listed cannabis firms in the 12‑month period ending Sep 30 2017.; Most companies had little to no revenue and were not profitable.; A single large $317 million financing by GW Pharmaceuticals occurred outside the reporting window.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.